Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | FNTA | P49354 | 10/20 | 0.45 |
| ▸ | FNTB | P49356 | 10/20 | 0.45 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SLC6A15 | Q9H2J7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32668926 | 1.00 | MAPK1 (0.53) | MAPK1SMN1; SMN2FNTAFNTBHRH1 | |
| SCHEMBL9832235 | 0.87 | MAPK1 (0.53) | MAPK1SMN1; SMN2FNTAFNTBDRD2 | |
| SCHEMBL8709456 | 0.86 | MAPK1 (0.72) | MAPK1SMN1; SMN2HRH1DRD2L3MBTL1 | |
| SCHEMBL5475539 | 0.85 | HRH1 (0.54) | MAPK1SMN1; SMN2FNTAFNTBHRH1 | |
| SCHEMBL8878464 | 0.85 | FNTA (0.43) | MAPK1SMN1; SMN2FNTAFNTBHRH1 | |
| SCHEMBL9592908 | 0.85 | SMN1; SMN2 (0.51) | MAPK1SMN1; SMN2FNTAFNTBHRH1 | |
| SCHEMBL8786099 | 0.84 | FNTA (0.42) | MAPK1SMN1; SMN2FNTAFNTBHRH1 | |
| SCHEMBL9590406 | 0.84 | MAPK1 (0.50) | MAPK1SMN1; SMN2DRD2L3MBTL1 | |
| SCHEMBL8877017 | 0.83 | MAPK1 (0.41) | MAPK1SMN1; SMN2FNTAFNTBHRH1 | |
| SCHEMBL9591624 | 0.83 | SMN1; SMN2 (0.49) | MAPK1SMN1; SMN2FNTAFNTBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005567-A1 | PROCESS FOR THE PREPARATION OF 4-(8-CHLORO-5,6-DIHYDRO-11H-BENZO (5,6)-CYCLOHEPTA-(1,2B) -PYRIDIN-11-YLIDENE)-1-PIPERIDINECARBOXYLIC ACID ETHYL ESTER (LORATADINE) | ZACH SYSTEM S.P.A. (IT) | 2009-01-01 | — | — | US | disclosed |
| US-7449583-B2 | Process for the preparation of 4-(8-chloro-5 6-dihydro-11h-benzo-(5 6)-cyclohepta-(1 2b)-pyridin-11-ylidene-1-piperidiniecarboxylic acid ethyl ester (loratadine) | ZACH SYSTEM S.P.A. (IT) | 2008-11-11 | — | — | US | disclosed |
| US-20070224266-A1 | Descarbonylethoxyloratadine containing pharmaceutical composition | PHARMASCIENCE INC. | 2007-09-27 | — | — | US | disclosed |
| EP-1442035-B1 | PROCESS FOR THE PREPARATION OF 4- (8-CHLORO-5, 6-DIHYDRO-11H-BENZO-[5,6]-CYCLOHEPTA-[1,2-B]-PYRIDIN-11-YLIDENE)-1-PIPERIDINECARBOXYLIC ACID ETHYL ESTER (LORATADINE) | ZAMBON SPA (IT) | 2006-01-11 | — | — | EP | disclosed |
| US-20050171352-A1 | Process for the preparation of 4-(8-chloro-5 6-dihydro-11h-benzo-(5 6)-cyclohepta-(1 2b)-pyridin-11-ylidene-1-piperidiniecarboxylic acid ethyl ester (loratadine) | ZAMBON GROUP S.P.A (IT) | 2005-08-04 | — | — | US | disclosed |
| WO-2004080997-A1 | PROCESS FOR THE PREPARATION OF LORATADINE | MOREPEN LABORATORIES LIMITED (IN) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005567-A1 | PROCESS FOR THE PREPARATION OF 4-(8-CHLORO-5,6-DIHYDRO-11H-BENZO (5,6)-CYCLOHEPTA-(1,2B) -PYRIDIN-11-YLIDENE)-1-PIPERIDINECARBOXYLIC ACID ETHYL ESTER (LORATADINE) | HRH4, HRH2, GRIN3A | MAPK1 3094/4885SMN1; SMN2 2562/4885FNTA 3989/4885 |
| US-20050171352-A1 | Process for the preparation of 4-(8-chloro-5 6-dihydro-11h-benzo-(5 6)-cyclohepta-(1 2b)-pyridin-11-ylidene-1-piperidiniecarboxylic acid ethyl ester (loratadine) | HRH4, HRH2, HRH1 | MAPK1 2708/4885SMN1; SMN2 3528/4885FNTA 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.